CIPD

GBS CIPDAwareness Month

May 2025

Support. Advocacy. Education.

*The Freedom™ Infusion System is not intended to be used for treatment of GBS and has not been cleared by the FDA for this use. Refer to the Freedom™ Infusion System IFU for specific indications for use and compatible immunoglobulins.

KORU is proud to support our CIDP patients and raise awareness during GBS CIDP Awareness Month. The Freedom™ Infusion System is FDA-cleared for the subcutaneous administration of immunoglobulins, including Hizentra®1,2, which is approved for the treatment of CIDP.3

At KORU, our mission is to empower patients with the freedom to truly live.

With our Freedom™ Infusion System and accessories, we want to give our patients freedom to receive medicine in harmony with the body’s natural processes.

Freedom to be wherever they choose (even within the comfort of their own home).

Freedom to simply be.

Read our full promise.

References

  1. U.S. Food and Drug Administration. (2021, December 15). 510(k) Summary: FREEDOM™ Integrated Syringe Infusion System (K200176). https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200176.pdf
  2. U.S. Food and Drug Administration. (2022, April 29). 510(k) summary: FreedomEdge® Syringe Infusion System (K214045). https://www.accessdata.fda.gov/cdrh_docs/pdf21/K214045.pdf
  3. U.S. Food and Drug Administration. (2018, March 15). Approval letter for Hizentra (STN: BL 125350/641)https://www.fda.gov/media/111603/download

Sign up for newsletter